Follow the Data: Sensitively detect subtle differences in CAR-T bioprocessing methods to advance decision making1

Research Area: Cell engineering & therapy

Development Stage: Optimization

Goal: Identify T cell cytokine production differences with varied bioprocessing methods

[unex_ce_button id="content_10khx0ih9,column_content_611g46odk" button_text_color="#ffffff" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px" button_bg_color="#24b7d8" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#24b7d8" button_border_radius="0px" button_text_hover_color="#ffffff" button_text_spacing_hover="1px" button_bg_hover_color="#84c9d8" button_border_hover_color="#84c9d8" button_link="" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Request a seminar
to follow our data >[/ce_button]

How our single-cell systems are making a difference

Solution:  IsoPlexis' systems  and flow cytometry provide the complete picture

Finding: Found consistently more robust, polyfunctional response in modified CAR-T manufacturing protocol

Follow the data

More robust polyfunctional response of CD4+ or CD8+ CAR-T cell products CD19 or CD22 with the modified manufacturing method (MM) compared to the original manufacturing method (OM).

Data demonstrates that the modified CD19/CD22 bispecific CAR-T cell manufacturing method (MM), which terminated T cell activation/transduction by culture day 3, resulted in reproducible and robust CAR-T cell production, even in the relatively more sensitive patient cells (left).1

[unex_ce_button id="content_om95el0ye,column_content_g32kkdowi" button_text_color="#424242" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px " button_bg_color="#c9c9c9" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#c9c9c9" button_border_radius="0px" button_text_hover_color="#424242" button_text_spacing_hover="1px" button_bg_hover_color="#e8e8e8" button_border_hover_color="#e8e8e8" button_link="" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Download application note
to learn more >[/ce_button]

IsoPlexis finds critical differences

Significantly higher viable TNC, Fold Expansion, Viability, Final CD3% and Transduction Efficiency in products manufactured using the MM compared to OM. Comparable CD4/CD8 ratios across the two methods.

All products using the MM met product release criteria. In addition, final product dose requirements were consistently met by culture day 7 when using the MM, augmenting process efficiency. 1

Unlock the IsoPlexis

Single-Cell Webinar Series 

Your data is in safe hands. View Privacy Policy

Unlock the IsoPlexis

Technology Overview Series

Your data is in safe hands. View Privacy Policy